Aripiprazole
Active ingredient description
It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.
Medicine classification
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Medicines
Aripiprazole is the active ingredient of these drugs:
Italy Tunisia
Spain
Australia Austria Canada Cyprus Estonia
Poland
South Africa
Australia
Spain
Brazil
Spain
Cyprus
Poland
Poland
South Africa
Estonia Lithuania
South Africa
Poland
Estonia Lithuania Poland
Austria
Germany
Poland
Germany
Hong Kong
Poland
Estonia Lithuania
Brazil
United States
South Africa
Spain
Brazil
Cyprus Germany
Poland
Germany United Kingdom
Poland
Hong Kong Poland
Poland
Spain
Brazil
Brazil
Cyprus
Poland
Brazil
Brazil
Brazil
Estonia Lithuania
Cyprus
Poland
South Africa
Brazil
Australia
Brazil
Spain
South Africa
South Africa
Cyprus Estonia Lithuania Spain
Product monographs
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):
Structural formula
Unique ingredient identifier (UNII)
82VFR53I78 - ARIPIPRAZOLE
CAS registry number
129722-12-9 - aripiprazole
SNOMED-CT
406784005 - Aripiprazole (substance)